Navigation Links
Mast Therapeutics Announces Management Change
Date:8/29/2014

he expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future studies of the Company's product candidates and the risk that its product candidates, including MST-188, may not demonstrate adequate safety, efficacy or tolerability in one or more such studies, including EPIC; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a "clinical hold," and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of a planned clinical study of a product candidate; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the potential that, even if clinical studies of a product candidate in one indication are successful, clinical studies in another indication may not be successful; the Company's reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of its product candidates, including clinical studies, manufacturing, and regulatory activities for its product candidates, and that such third parties may fail to perform as expected; the Company's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for the Company to delay, reduce or discontinue current and/or planned development activities, including clinica
'/>"/>
SOURCE Mast Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ... million, a 10 percent increase compared to the quarter ended ... currency basis). Net income was $91.2 million, an increase of ... Diluted earnings per share for the quarter were $0.64, an ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... DIEGO, Sept. 27 Clinicians from three U.S. hospitals ... IV catheter-related bloodstream infections (CRBSI). Data analyzed and presented ... Springs, Ark.; Bethesda North Hospital in Cincinnati; and the ... virtually eliminated such infections, which annually kill some 62,500 ...
... The Colorado Institute for Drug, Device and Diagnostic Development ... solicitation announced in February.  The announcement is made by ... Sophono, Inc., is receiving $600,000 for its Alpha 1 ... is receiving $300,000 for its universal flu vaccine under ...
Cached Medicine Technology:Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 2Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 3Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 4The Colorado Institute for Drug, Device and Diagnostic Development Announces Companies Selected From Its First Solicitation: Sophono, Inc., Receiving $600K; and PeptiVir, Inc., $300K 2
(Date:1/23/2015)... Hastings and Hastings, a law firm in Arizona that ... legal representation client review requests for slip and fall accidents ... in the number of slip and fall related accidents that ... With that said, a large number of injury victims are ... firm. Hastings and Hastings is a personal injury firm in ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 The U.S. ... R.Ph., DICVP, Director of Clinical Pharmacy Services at North ... the recipient of the 2015 Beal Award for Distinguished ... USP has relied on the contributions of volunteer experts ...
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... 2015 Woodloch Pines, an all-inclusive family ... by TripAdvisor as the number one best large hotel for ... the world for their annual Travelers’ Choice Awards. , ... The website is home to millions of unbiased and honest ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3
... on State,Children,s Health Insurance Program (SCHIP), WASHINGTON, ... Thanksgiving break with a clear conscience before it ... by passing an adequately,funded SCHIP bill," said Dr. ... Alliance for Hispanic Health, the nation,s leading Hispanic ...
... is most likely to experience osteoarthritis, and to test whether ... their sights on people who sustain a knee injury, seeking ... on to develop osteoarthritis, a debilitating condition that causes pain ... , The work is funded by a special class ...
... C. Benjamin, MD, FACP, FACEP (E) Executive ... 18 The following statement,by Georges C. Benjamin, ... Health Association., "The American Public Health Association ... of Representatives to uphold the intent of the,overwhelming ...
... 18 Medical Decisions Network,(MDN) announces Food and ... Insulin Dosing Software. The MDN-CGS software is used,by ... dosage of,intravenous insulin administered to patients with elevated ... the body converts to energy for survival. ...
... old age linked to mental woes, study finds , THURSDAY, ... may boost the risk of dementia later in life, U.S. ... analyzed the dental records and annual cognitive test results of ... an examination of aging and Alzheimer,s disease among sisters of ...
... the,leading global provider of dosage form solutions, announced ... have now been licensed by,eight of the top ... Licaps(R) Drug Delivery System, these companies are using ... stage,development and manufacturing of Phase 1 clinical trial ...
Cached Medicine News:Health News:What's been causing your knee to ache? Smurfs! 2Health News:What's been causing your knee to ache? Smurfs! 3Health News:Nation's Children are the Only Losers in Failure to Override CHIP Veto 2Health News:FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software 2Health News:Capsugel's Liquid Dosage Form Technology Utilized by Eight of the Top 10 Pharmaceutical Companies 2
... and Evisceration. The new MEDPOR ... standard MEDPOR Spheres with a bioactive ... mixed throughout the sphere structure, promotes ... MEDPOR PLUS sphere., ,MEDPOR is a ...
... Cadwell's custom bars have a large ... machined contacts (spaced 3 centimeters center-to-center) ... of repeated cleaning. Polarity indicators are ... snap-on handle fits our bar electrode ...
... Cadwell's custom bars have a ... solid, machined contacts (spaced 3 centimeters ... tear of repeated cleaning. Polarity indicators ... convenient, snap-on handle fits our bar ...
... IOL is the first lens of its kind ... the reduction or elimination of myopia in adults ... and in patients aged 21 and over. ... procedures performed worldwide, results prove that the Verisyse ...
Medicine Products: